| Name | MLN-4760 |
| Description | MLN-4760 is an angiotensin-converting (ACE2) inhibitor(human ACE2;IC50=0.44 nM). It also has excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM). |
| In vitro | MLN-4760 displays pIC50 at rhACE2 of 8.5±0.1 and at rhACE of 4.4±0.2. MLN-4760 also shows pIC50 at rhACE2 of 4.7±0.1, 6.9±0.1, and an ACE of 4.4±0.1, 6.2±0.1 in murine heart and mononuclear cells (MNCs), respectively. MLN-4760 potently quenches the cleavage of the 7-Mca-YVADAPK(Dnp) in rhACE2[2]. |
| In vivo | MLN-4760 (100 μM, intracerebroventricular infusion for five days) significantly exacerbates neurological function at 4 hours and 3 days post-stroke, without a notable increase in infarct volume[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.67 mM), Sonication is recommended.
|
| Keywords | MLN-4760 | MLN4760 | MLN 4760 | Inhibitor | inhibit | Human ACE2 | Bovine carboxypeptidase A | Angiotensin-converting Enzyme (ACE) | ACE |
| Inhibitors Related | H-ASP-PHE-OH | Losartan potassium | Tranilast | Telmisartan | Lisinopril dihydrate | Sacubitril/Valsartan | Ursodeoxycholic acid | Benzyl benzoate | Irbesartan | Losartan | Diisononyl phthalate | Captopril |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Multi-Target Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Endocrinology-Hormone Compound Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |